WP
Woodline Partners LP disclosed a 5.7% stake in SABS
Woodline Partners LP reported owning 5.7% of SAB Biotherapeutics, Inc. (SABS) (5,455,694 shares) in a Schedule 13G filed Nov 16, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
- Disclosed
- Nov 16, 2026
- Source
- Schedule 13G